Mastering Mucosal Defense To protect people from infectious diseases

Lovaltech is a clinical-stage deeptech biotech, founded in 2022 as a spin-off from the University of Tours and INRAE.

Our mucosal delivery platform, LVT-NEXUS, is built on LVT-ME, a proprietary muco-excipient. It is designed to adapt to different payloads, and to different diseases.

Its first product, LVT-001, an intranasal vaccine against COVID-19, completed Phase 1 with a favorable safety and tolerability profile. Phase 2 starts in November 2026. Voir l’essai sur ClinicalTrials.gov.

We create value through our own products, platform licensing and co-development.

1. A platform that adapts to different payloads (protein, RNA, viruses ...).
2. Mucosal delivery targeted by our proprietary muco-excipient, LVT-ME.
3. Needle-free nasal administration, simple for patients and health professionals, non-invasive.
4. A protected technology with patents. 
5. Expertise in mucosal immunity and protein engineering to develop new vaccine candidates.
6. An open model (licensing and co-development), backed by a first clinical-stage candidate: LVT-001, with Phase 2 starting in November 2026.